Jefferies initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $8 price target The stock looks inexpensive as its novel imatinib oral pro-drug IkT-001Pro will enter Phase 2B for PAH, with an added free Parkinson’s call option for oral risvodetinib, where expectations are super low, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics Secures Funding and Strengthens Leadership
- Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
- Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
- Inhibikase Therapeutics Secures $110M for Drug Development
- Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement